Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $21.82, for a total value of $272,750.00. Following the transaction, the chief executive officer directly owned 890,392 shares of the company’s stock, valued at $19,428,353.44. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Friday, October 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.33, for a total value of $266,625.00.
• On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.06, for a total value of $74,222.00.
• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $95,450.00.

Enliven Therapeutics Price Performance

Shares of ELVN stock traded down $0.49 during trading hours on Wednesday, reaching $22.10. The stock had a trading volume of 440,423 shares, compared to its average volume of 422,253. The firm has a market capitalization of $1.31 billion, a PE ratio of -12.01 and a beta of 0.80. The firm has a 50-day simple moving average of $20.32 and a 200-day simple moving average of $20.11. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $26.48.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ELVN. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics in the first quarter worth approximately $60,000. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. AlphaQuest LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth $96,000. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.